查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108289

AI老藥新用(藥物功能重新定位)市場分析及預測（至2035年）：按類型、產品、服務、技術、組件、應用、流程、最終用戶和解決方案分類

AI for Drug Repurposing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球AI老藥新用市場預計將從2025年的13億美元成長到2035年的71億美元，複合年成長率（CAGR）為18.4%。在製藥業對人工智慧和計算生物學投入不斷增加的推動下，該市場持續擴張。根據美國國立衛生研究院（NIH）的官方數據，全球已註冊數千項與藥物重定位相關的臨床研究，顯示相關研究活動激增。美國食品藥物管理局（FDA）持續批准透過增加適應症而開發的療法，進一步提升了企業對藥物重定位策略的商業性興趣。隨著製藥公司擴大利用機器學習來縮短藥物研發週期、最佳化候選化合物的優先排序並降低研發成本，全球醫療保健領域的人工智慧投資正在加速成長，預計未來十年該市場將保持兩位數的成長率。

服務部門在幫助企業實施和最佳化AI老藥新用解決方案方面發揮著至關重要的作用，這些解決方案將應用於企業整個製藥和生物技術工作流程。諮詢服務專注於人工智慧策略、法規遵循規劃和工作流程最佳化，而整合服務則將人工智慧平台與實驗室資訊管理系統、臨床資料庫和基因組庫連接起來。維護服務確保軟體持續更新、網路安全和系統效能，而培訓和支援則提升員工解讀人工智慧模型和管理資料的能力。在雲端分析技術日益普及、人工智慧部署外包業務不斷成長以及對客製化生物資訊解決方案的需求持續成長的推動下，業務收益在整個預測期內將保持強勁成長。

市場區隔
類型 機器學習、深度學習、自然語言處理及其他
產品 軟體、平台及其他
服務 諮詢、實施、支援和維護以及其他服務。
科技 雲端部署、本地部署、混合部署及其他
成分 人工智慧演算法、資料管理工具、分析等等。
目的 腫瘤科、循環系統、神經科、感染疾病、罕見病科等。
流程 標靶識別、藥物篩檢、臨床試驗、上市後監測等。
最終用戶 製藥公司、生技公司、研究機構、受託研究機構及其他
解決方案 藥物發現、藥物開發、現有藥物新適應症的開發等相關領域。

解決方案領域涵蓋人工智慧平台，這些平台透過預測分析和計算建模來改進藥物創新的各個階段。藥物發現解決方案能夠識別新的生物標靶並有效篩檢分子庫。另一方面，藥物開發解決方案則最佳化臨床前檢驗、生物標記識別和臨床試驗設計。藥物再利用解決方案利用基因組學、蛋白質組學和臨床資料集來識別已通過核准或在臨床實驗藥物的新適應症。這些解決方案能夠縮短研究週期、提高決策準確性並降低開發風險。深度學習演算法、多模態資料整合和可解釋人工智慧的持續進步有望進一步加速這些解決方案在整個藥物研究生態系統中的應用。

區域概覽

北美憑藉其先進的醫藥生態系統、完善的生物醫學研究基礎設施以及人工智慧技術的廣泛應用，在AI老藥新用市場中保持主導地位。大型製藥公司、生物技術創新者、雲端運算供應商和學術研究機構的聚集，創造了協作創新的環境。公共衛生機構的大力資助、完善的臨床試驗網路以及強力的智慧財產權保護，正推動著人工智慧驅動的藥物再利用平台快速商業化。對精準醫療、基因組研究和數位健康舉措的持續投入，進一步增強了該地區的競爭力，並支持其長期市場擴張。

亞太地區正透過擴大製藥生產能力、加大人工智慧研究投入以及發展數位醫療基礎設施，展現出巨大的市場潛力。中國、日本、韓國、印度和新加坡等國家正在加強國家層面的人工智慧策略，並透過官民合作關係和研究資助支持生物技術創新。醫療保健支出的成長、生物醫學資料集的日益豐富以及科技公司與製藥公司之間合作的不斷深化，正在加速相關解決方案的普及應用。預計在預測期內，臨床研究活動的拓展、政府的支持措施以及雲端運算基礎設施的改善將進一步提升該地區對AI老藥新用平台的需求。

主要趨勢和促進因素

人工智慧與巨量資料分析的融合：

在AI老藥新用市場，巨量資料分析正被日益廣泛地用於提高藥物發現過程的準確性和效率。透過將人工智慧與來自臨床試驗、基因組研究和患者記錄的大量資料集相結合，企業可以更快、更準確地識別出有前景的候選藥物。這一趨勢的驅動力源於降低傳統藥物發現所需時間和成本的需求，以及醫療保健數據日益成長的可用性。

人工智慧加速了藥物適應症的快速、低成本擴展：

降低藥物研發成本和縮短產品上市時間的壓力日益增大，這是AI老藥新用市場的主要驅動力。傳統的藥物研發仍成本高且耗時，因此各機構紛紛利用人工智慧來識別現有化合物的新適應症，這些化合物已具有良好的安全性記錄。大規模生物醫學資料集的可用性、不斷提升的運算能力以及製藥公司、人工智慧開發商和研究機構之間日益密切的合作，都在推動市場對人工智慧的持續應用和投資。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 機器學習
    • 深度學習
    • 自然語言處理
    • 其他
  • 市場規模及預測：依產品分類
    • 軟體
    • 平台
    • 其他
  • 市場規模及預測：依服務分類
    • 諮詢
    • 執行
    • 支援與維護
    • 其他
  • 市場規模及預測：依技術分類
    • 基於雲端的
    • 現場
    • 混合
    • 其他
  • 市場規模及預測：依組件分類
    • 人工智慧演算法
    • 資料管理工具
    • 分析
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 循環系統
    • 神經病學
    • 感染疾病
    • 罕見疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 受託研究機構
    • 其他
  • 市場規模及預測：依製程分類
    • 確定目標
    • 藥物篩檢
    • 臨床試驗
    • 上市後監測
    • 其他
  • 市場規模及預測：按解決方案分類
    • 藥物發現
    • 藥物研發
    • 藥物重新定位
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Insilico Medicine
  • Atomwise
  • BenevolentAI
  • Exscientia
  • Recursion Pharmaceuticals
  • Cyclica
  • Healx
  • BioXcel Therapeutics
  • GNS Healthcare
  • NuMedii
  • Pharnext
  • Insitro
  • Deep Genomics
  • Cloud Pharmaceuticals
  • Standigm
  • AI Therapeutics
  • XtalPi
  • BERG Health
  • PathAI
  • A2A Pharmaceuticals

第9章 關於我們

簡介目錄
Product Code: GIS10829

The global AI for Drug Repurposing Market is projected to grow from $1.3 billion in 2025 to $7.1 billion by 2035, at a compound annual growth rate (CAGR) of 18.4%. The AI for Drug Repurposing Market continues to expand alongside increasing pharmaceutical investment in artificial intelligence and computational biology. According to official data from the National Institutes of Health (NIH), thousands of drug repurposing-related clinical studies are registered globally, reflecting growing research activity. The U.S. Food and Drug Administration (FDA) continues to approve therapies developed through supplemental indications, reinforcing commercial interest in repurposing strategies. Global AI investment in healthcare has accelerated as pharmaceutical companies increasingly deploy machine learning to shorten discovery timelines, improve candidate prioritization, and reduce research costs, supporting double-digit market growth expectations over the coming decade.

The services segment plays a critical role in enabling organizations to deploy and optimize AI-driven drug repurposing solutions across pharmaceutical and biotechnology workflows. Consulting services focus on AI strategy, regulatory planning, and workflow optimization, while integration services connect AI platforms with laboratory information management systems, clinical databases, and genomic repositories. Maintenance services ensure continuous software updates, cybersecurity, and system performance, whereas training and support improve workforce proficiency in AI model interpretation and data management. Growing adoption of cloud-based analytics, increasing outsourcing of AI implementation, and expanding demand for customized bioinformatics solutions are expected to sustain strong service revenues throughout the forecast period.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing, Others
ProductSoftware, Platform, Others
ServicesConsulting, Implementation, Support and Maintenance, Others
TechnologyCloud-based, On-premise, Hybrid, Others
ComponentAI Algorithms, Data Management Tools, Analytics, Others
ApplicationOncology, Cardiology, Neurology, Infectious Diseases, Rare Diseases, Others
ProcessTarget Identification, Drug Screening, Clinical Trials, Post-market Surveillance, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations, Others
SolutionsDrug Discovery, Drug Development, Drug Repositioning, Others

The solutions segment encompasses AI platforms that improve different stages of pharmaceutical innovation through predictive analytics and computational modeling. Drug discovery solutions identify novel biological targets and screen molecular libraries efficiently, while drug development solutions optimize preclinical validation, biomarker identification, and clinical trial design. Drug repositioning solutions leverage genomic, proteomic, and clinical datasets to identify alternative therapeutic indications for approved or investigational drugs. These solutions reduce research timelines, improve decision accuracy, and lower development risks. Continuous advancements in deep learning algorithms, multimodal data integration, and explainable AI are expected to strengthen solution adoption across pharmaceutical research ecosystems.

Geographical Overview

North America maintains a leading position in the AI for Drug Repurposing Market due to its advanced pharmaceutical ecosystem, extensive biomedical research infrastructure, and widespread adoption of artificial intelligence technologies. The presence of major pharmaceutical manufacturers, biotechnology innovators, cloud computing providers, and academic research institutions creates a collaborative innovation environment. Strong funding from public health agencies, well-established clinical trial networks, and favorable intellectual property protection encourage rapid commercialization of AI-enabled drug repurposing platforms. Continuous investments in precision medicine, genomic research, and digital health initiatives further strengthen regional competitiveness and sustain long-term market expansion.

Asia-Pacific demonstrates substantial market potential through expanding pharmaceutical manufacturing capabilities, increasing AI research investments, and growing digital healthcare infrastructure. Countries including China, Japan, South Korea, India, and Singapore are strengthening national AI strategies while supporting biotechnology innovation through public-private partnerships and research funding. Rising healthcare expenditure, increasing availability of biomedical datasets, and growing collaborations between technology companies and pharmaceutical organizations are accelerating solution deployment. Expansion of clinical research activities, supportive government initiatives, and improvements in cloud computing infrastructure are expected to reinforce regional demand for AI-driven drug repurposing platforms over the forecast period.

Key Trends and Drivers

Integration of AI with Big Data Analytics:

The AI for drug repurposing market is increasingly leveraging big data analytics to enhance the accuracy and efficiency of drug discovery processes. By integrating AI with vast datasets from clinical trials, genomic studies, and patient records, companies can identify potential drug candidates more quickly and accurately. This trend is driven by the need to reduce the time and cost associated with traditional drug development, as well as the growing availability of healthcare data.

AI Accelerates Faster and Cost-Efficient Drug Repurposing:

Growing pressure to reduce pharmaceutical research costs and accelerate time-to-market is the primary driver of the AI for Drug Repurposing Market. Conventional drug development remains expensive and time-intensive, prompting organizations to leverage AI for identifying new indications for existing compounds with established safety profiles. The availability of large biomedical datasets, expanding computational capabilities, and increased collaborations between pharmaceutical companies, AI developers, and research institutions continue to strengthen market adoption and investment.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Platform
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Implementation
    • 4.3.3 Support and Maintenance
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premise
    • 4.4.3 Hybrid
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 AI Algorithms
    • 4.5.2 Data Management Tools
    • 4.5.3 Analytics
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiology
    • 4.6.3 Neurology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Rare Diseases
    • 4.6.6 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Institutes
    • 4.7.4 Contract Research Organizations
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Target Identification
    • 4.8.2 Drug Screening
    • 4.8.3 Clinical Trials
    • 4.8.4 Post-market Surveillance
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Drug Discovery
    • 4.9.2 Drug Development
    • 4.9.3 Drug Repositioning
    • 4.9.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Insilico Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atomwise
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 BenevolentAI
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Exscientia
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Recursion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Cyclica
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Healx
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 BioXcel Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 GNS Healthcare
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 NuMedii
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pharnext
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Insitro
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Deep Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cloud Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Standigm
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 AI Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 XtalPi
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 BERG Health
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 PathAI
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 A2A Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us